MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.04
+0.30 (+2.18%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close13.74
Open14.14
Bid14.02 x 4000
Ask13.99 x 4000
Day's Range13.76 - 14.65
52 Week Range12.75 - 28.46
Volume9,635,466
Avg. Volume7,615,385
Market Cap7.247B
Beta (5Y Monthly)1.62
PE Ratio (TTM)468.00
EPS (TTM)0.03
Earnings DateMay 04, 2020 - May 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 26, 2007
1y Target Est23.07
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Pfizer's Upjohn Combo With Mylan Is Delayed — What That Means For PFE Stock
    Investor's Business Daily

    Pfizer's Upjohn Combo With Mylan Is Delayed — What That Means For PFE Stock

    Pfizer stock could see some gains in 2020 if it makes progress on a coronavirus vaccine with BioNTech. But its Upjohn merger with Mylan is now delayed. Is Pfizer stock a buy now?

  • Reuters

    RPT-Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19

    Novartis and Incyte plan to test their drug Jakavi in patients with coronavirus-caused COVID-19, joining other firms including Roche and Sanofi hoping to repurpose older medicines to help critically ill patients. Jakavi is used in adults with bone marrow cancer, or myelofibrosis, among other conditions. Novartis and Incyte want to see if it helps COVID-19 patients suffering from an immune system overreaction, also called a cytokine storm.

  • Novartis Terminates Sale of Sandoz Dermatology Business
    Zacks

    Novartis Terminates Sale of Sandoz Dermatology Business

    Novartis (NVS) terminates sale of Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA Inc.

  • How Much Are Mylan N.V. (NASDAQ:MYL) Insiders Spending On Buying Shares?
    Simply Wall St.

    How Much Are Mylan N.V. (NASDAQ:MYL) Insiders Spending On Buying Shares?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

  • Mylan offers concessions to address EU concerns about Pfizer deal
    Reuters

    Mylan offers concessions to address EU concerns about Pfizer deal

    Generic drugmaker Mylan NV has offered concessions to address European Union antitrust concerns about its bid for Pfizer's off-patent branded drugs business Upjohn, a filing on the European Commission site showed on Monday. U.S. drugmaker Pfizer announced the deal in July as part of a strategy allowing it to focus on its more profitable newer medicines. The European Commission set an April 22 deadline for its decision after Mylan put in its offer on March 27.

  • Drug makers on shaky ground as clinical trials are postponed and drug launches delayed amid pandemic
    MarketWatch

    Drug makers on shaky ground as clinical trials are postponed and drug launches delayed amid pandemic

    Bristol-Myers Squibb Co.’s decision to hold off launching Zeposia, its newly approved multiple sclerosis treatment, underscores how disruptive the COVID-19 pandemic is to a trillion-dollar industry that relies heavily on collaborative working and meeting milestones that satiate investors.

  • Mylan (MYL) Down 20.3% Since Last Earnings Report: Can It Rebound?
    Zacks

    Mylan (MYL) Down 20.3% Since Last Earnings Report: Can It Rebound?

    Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GuruFocus.com

    Covid-19 Could Benefit Generic Drug Companies

    Pricing is increasing for makers of copycat medicines Continue reading...

  • Coronavirus Drugs Already in the Pipeline
    Kiplinger

    Coronavirus Drugs Already in the Pipeline

    It's not just chloroquine. Other existing medicines are being brought to bear against COVID-19. We look at what drugs have promise against COVID-19, and when they will get here.

  • PR Newswire

    Mylan and Lupin Announce Positive CHMP Opinion for Nepexto®, Biosimilar Etanercept

    Mylan N.V. (NASDAQ: MYL) and Lupin Limited (Lupin) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Nepexto®, a biosimilar to Enbrel® (etanercept), for all indications of the reference product including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.

  • Barrons.com

    Pfizer and Mylan Postpone Upjohn Deal. Analysts Aren’t Worried.

    The news is the latest sign of the dramatic impact that the Covid-19 pandemic is having across the health care industry.

  • The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger
    Benzinga

    The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 25.) * Ra Pharmaceuticals Inc (NASDAQ: RARX)Down In The Dumps (Biotech stocks that hit 52-week lows March 25.) * Anixa Biosciences Inc (NASDAQ: ANIX) * IMMUTEP LTD/S ADR (NASDAQ: IMMP) (reacted to breast cancer trial readout) * PLx Pharma Inc (NASDAQ: PLXP) * Taro Pharmaceutical Industries Ltd. (NYSE: TARO)Stocks In Focus Quidel COVID-19 Detection Assay Obtains Expanded EUA, CE Mark Approval Quidel Corporation (NASDAQ: QDEL) said its Lyra SARS-CoV-2 Assay has received expanded Emergency Use Authorization from the FDA to allow testing with three additional thermocyclers, namely Applied Biosystems' 7500, Roche Holdings AG's (OTC: RHHBY) LightCycler 480 and Qiagen NV's (NYSE: QGEN) Rotor Gene Q.Quidel said the initial EUA awarded allowed qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal or oropharyngeal swab specimens from patients suspected of COVID-19. The expanded authorization includes nasal and nasal turbinate swabs.Quidel also said it received the CE-Mark on March 25, which will allow it market and sell the Lyra SARS-CoV-2 Assay in Europe as well as other countries that accept CE Mark.Alector Out-Licenses China Rights of AL008 In Oncology To Innovent Biologics Alector Inc (NASDAQ: ALEC) and Hong Kong-listed biopharma Innovent Biologics said they have entered into a licensing agreement to develop and commercialize an anti-SIRP-alpha antibody AL008 for the treatment of oncology indications in China.The companies did not disclose the financial terms of the deal. The agreement gives Innovent the responsibility of leading development and commercialization of the investigational compound in China, while Alector is in charge of developmental activities outside of China.See also: The Week Ahead In Biotech: Bristol-Myers, Rockwell Medical Await FDA Decisions, COVID-19 Updates In Focus Bristol-Myers Squibb Receives FDA Nod For Celgene's Multiple Sclerosis Drug Bristol-Myers Squibb Co (NYSE: BMY) announced FDA approval for ozanimod 0.92 mg as a treatment option for patients with relapsing forms of multiple sclerosis.In premarket trading Thursday, Bristol-Myers Squibb shares were adding 1.52% to $50.10.Cerecor To Test Role Of Inflammatory Cytokinin In COVID-19-Induced Acute Respiratory Distress Cerecor Inc (NASDAQ: CERC) said it plans to explore the role of an inflammatory cytokine -- LIGHT -- in patients with COVID-19-induced acute respiratory distress. It said it will use its proprietary free LIGHT assay as well as multiple assay to determine if there are differences in LIGHT levels and other inflammatory markers, including IL-18 and IFN-g, in patients with mild-to-moderate vs. severe disease with Acute Lung Injury or Acute Respiratory Distress Syndrome.Grifols To Develop Hyperimmune Globulin For COVID-19 Grifols SA - ADR (NASDAQ: GRFS) said it has entered a formal collaboration agreement with the U.S. BARDA, the FDA and other federal public health agencies to collect plasma from convalescent COVID-19 patients and process this specific plasma into a hyperimmune globulin.The company also said it will support the necessary preclinical and clinical studies to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can be used to treat COVID-19 disease.In Spain, Grifols is working on a clinical trial with inactivated plasma from recovered patients through a collaboration with select donation centers and public hospitals.View more earnings on IBBThe company also said it has accelerated the development and validation of a proprietary technology transcription-mediated amplification-based diagnostic procedure to detect the virus, with a sensitivity equivalent or even superior to that of PCR test.The stock was rising 10.47% to $19.63 in premarket trading.Pfizer, Mylan Announce Delay In Merger Of Generic Businesses Pfizer Inc. (NYSE: PFE) and Mylan NV (NASDAQ: MYL) announced the proposed merger between Mylan and Pfizer's generic unit Upjohn will now close in the second half of 2020 due to the unprecedented circumstances surrounding the COVID-19 pandemic, including associated delays in the regulatory review process. The companies initially had a closing deadline of mid-2020.Biopharmx Gets Delisting Notice From NYSE American Specialty pharma company Biopharmx Corp (NYSE: BPMX) said it received a notification from NYSE American LLC on March 24 regarding its determination to delist the company's shares from the exchange. The decision is due to the company's non-compliance with certain continued listing standards.Biopharmx said it will appeal the delisting notice. The shares, according to the company, will continue to trade on the exchange during the appeal period.The company also clarified that the delisting does not affect its business operations, its intention to merge with Timber Pharma announced Jan. 28 or its SEC reporting requirements,The stock was down 2.83% at 28 cents at the time of publication.Xencor, Vir Agree To License Technology To Extend Half-Life Of COVID-19 Treatment Candidates Xencor Inc (NASDAQ: XNCR) said it entered into a technology license agreement with Vir Biotechnology Inc (NASDAQ: VIR) that provides Vir non-exclusive access to Xencor's Xtend Fc technology to extend the half-life of novel antibodies Vir is investigating as a potential treatment for COVID-19."Xtend Fc technology has demonstrated, in multiple antibodies and through numerous human clinical trials, the ability to extend antibody drug half-life and reduce dosing frequency in patients, an important feature in anti-viral therapy for pandemic use," Xencor CEO Bassil Dahiyat said in a statement. The companies did not disclose the financial terms of the deal.Vir shares were trading 3.22% higher at $31.74 in Thursday's premarket session.Earnings Biocept Inc's (NASDAQ: BIOC) fourth-quarter revenue climbed 108% year-over-year to $1.8 million. The net loss narrowed significantly from $1.43 per share to 20 cents per share. Analysts estimated a loss of 10 cents per share.The stock was trading 8.57% higher at 38 cents at the time of publication. On The Radar PDUFA Dates IntelGenx Technologies Corp.'s (OTC: IGXT) NDA for rizaport versafilm for the treatment of acute migraine is pending before the FDA, with the target action day fixed for Thursday. The company had faced three rejections for the investigational drug in the past.Earnings * Celsion Corporation (NASDAQ: CLSN) (before the market open) * Entera Bio Ltd (NASDAQ: ENTX) (before the market open) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) (before the market open) * IGM Biosciences Inc (NASDAQ: IGMS) (after the close) * NovaBay Pharmaceuticals, Inc. (NYSE: NBY) (after the close) * Vermillion, Inc. (NASDAQ: VRML) (after the close) * aTyr Pharma Inc (NASDAQ: LIFE) (after the close)Related Link: Hoth Therapeutics Shares Jump On COVID-19 Vaccine Development Plans See more from Benzinga * The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Mylan delays merger with Upjohn due to COVID-19 pandemic
    American City Business Journals

    Mylan delays merger with Upjohn due to COVID-19 pandemic

    The Mylan NV-Upjohn merger is being pushed back into the second half of 2020 due to the COVID-19 global pandemic. Mylan NV (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE), which owns Upjohn, announced Thursday that COVID-19 is moving the expected merger date from the first half of the year and Mylan's meeting of shareholders to approve it is being moved from April 27 to June 30. Mylan and Upjohn announced last July that they would be merging to create a global pharmaceutical giant, in both generic and brand name drugs.

  • Drugmakers Mylan, Pfizer delay merger due to coronavirus outbreak
    Reuters

    Drugmakers Mylan, Pfizer delay merger due to coronavirus outbreak

    Due to restrictions on large gatherings, the general meeting of shareholders to approve certain matters for the deal to go through has been postponed to June 30, Mylan said. There were no other changes to previously announced terms or plans pertaining to the deal, previously expected to close in mid-2020, the companies said. The merger, which will bring blockbuster treatments Viagra and Lipitor from Pfizer under one umbrella with Mylan's EpiPen, is part of years-long effort by Pfizer to split into three parts - innovative medicines, lower margin off-patent drugs facing generic competition and consumer healthcare.

  • Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn
    PR Newswire

    Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn

    Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced that due to the unprecedented circumstances surrounding the COVID-19 pandemic, including associated delays in the regulatory review process, the proposed transaction involving Mylan and Upjohn, a division of Pfizer, is now anticipated to close in the second half of 2020.

  • Barrons.com

    Mylan Says India’s Coronavirus Lockdown Won’t Affect Drug Production

    Shares of the generic drugmaker (MYL)were down Wednesday, amid worry over how India’s abrupt decision to effectively ban its citizens from leaving their homes would affect drugmakers. While China is reportedly the world’s largest producer of the active pharmaceutical ingredients used to make drugs, India is a major manufacturer of generic drugs themselves. In a statement on Wednesday, Mylan said drug factories are exempt from the stay-at-home order issued Tuesday, and that Mylan’s facilities in India are continuing to operate.

  • Mylan Announces Additional Efforts to Support Response to the COVID-19 Pandemic by Voluntarily Waiving its Marketing Exclusivity in the U.S. for Lopinavir/Ritonavir to Help Ensure Wider Availability to Meet Potential COVID-19 Patient Needs
    PR Newswire

    Mylan Announces Additional Efforts to Support Response to the COVID-19 Pandemic by Voluntarily Waiving its Marketing Exclusivity in the U.S. for Lopinavir/Ritonavir to Help Ensure Wider Availability to Meet Potential COVID-19 Patient Needs

    Mylan (NASDAQ: MYL) today announced that, in its ongoing effort to support patients and public health needs in the current unprecedented circumstances surrounding the COVID-19 pandemic, Mylan has voluntarily waived its exclusive rights in the U.S. to distribute its generic version of Kaletra® (lopinavir/ritonavir) antiretroviral 100mg/25mg and 200mg/50mg tablets to help increase the available supply of the product should it prove effective in the treatment of coronavirus. By doing so, Mylan will enable other generic applicants to be eligible for FDA approval of their medicines for patients in the U.S., expanding access in the event that additional clinical studies or other evaluations conclude that the product may be effective in treating COVID-19.

  • Moody's

    Pfizer Inc. -- Moody's assigns A1 to Pfizer's notes, on review for downgrade

    Moody's Investors Service ("Moody's") assigned an A1 rating to the new senior unsecured notes being issued by Pfizer Inc. ("Pfizer"). This rating is under review for downgrade, consistent with other senior unsecured ratings of Pfizer. There are no changes to Pfizer's existing ratings including the A1 long term rating (under review for downgrade) and the Prime-1 commercial paper rating (not under review for downgrade).

  • Pfizer Is Entering The Coronavirus Drug Hunt — But Is PFE Stock A Buy?
    Investor's Business Daily

    Pfizer Is Entering The Coronavirus Drug Hunt — But Is PFE Stock A Buy?

    Pfizer stock is on a recent downswing in the wake of lackluster fourth-quarter earnings, though the company is partnering on a coronavirus vaccine. Is the pharma company a buy right now?

  • Barrons.com

    Companies Plan to Boost Production of Controversial Malaria Drug as Demand Jumps

    Demand for hydroxychloroquine, the malaria drug that President Trump has touted as a treatment for Covid-19 despite limited evidence, has already begun to increase, according to a note from SVB Leerink analyst Ami Fadia.

  • Trump makes the case for chloroquine as a COVID-19 treatment, though it has not been approved by the FDA for this illness
    MarketWatch

    Trump makes the case for chloroquine as a COVID-19 treatment, though it has not been approved by the FDA for this illness

    President Donald Trump and the Food and Drug Administration commissioner appeared to exchange conflicting statements about how a decades-old antimalaria drug is being used to treat COVID-19.

  • Coronavirus update: 284,566 cases, 11,868 deaths, New York and Illinois in lockdown
    MarketWatch

    Coronavirus update: 284,566 cases, 11,868 deaths, New York and Illinois in lockdown

    The U.S. is wrapping up the first full business week feeling the brunt of the COVID-19 pandemic, with restaurants, bars, parks, retailers and workplaces shut down in many cities across the nation and three states in lockdown.